Advertisement
Australia markets close in 3 hours 19 minutes

  • ALL ORDS

    8,005.80
    -70.90 (-0.88%)
     

  • ASX 200

    7,733.20
    -71.30 (-0.91%)
     

  • AUD/USD

    0.6575
    -0.0007 (-0.11%)
     

  • OIL

    79.37
    +0.38 (+0.48%)
     

  • GOLD

    2,315.60
    -6.70 (-0.29%)
     

  • Bitcoin AUD

    93,742.52
    -1,780.65 (-1.86%)
     

  • CMC Crypto 200

    1,312.40
    +17.73 (+1.37%)
     

  • AUD/EUR

    0.6116
    -0.0001 (-0.02%)
     

  • AUD/NZD

    1.0951
    +0.0002 (+0.02%)
     

  • NZX 50

    11,707.34
    -75.55 (-0.64%)
     

  • NASDAQ

    18,085.01
    -6.43 (-0.04%)
     

  • FTSE

    8,354.05
    +40.38 (+0.49%)
     

  • Dow Jones

    39,056.39
    +172.13 (+0.44%)
     

  • DAX

    18,498.38
    +68.33 (+0.37%)
     

  • Hang Seng

    18,424.05
    +110.19 (+0.60%)
     

  • NIKKEI 225

    38,392.10
    +189.73 (+0.50%)
     

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SpringWorks Therapeutics, Inc.
·1-min read

STAMFORD, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.

A video webcast will be available on the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology portfolio of small molecule product candidates and is advancing 17 development programs, including two potentially registrational clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to expand its portfolio and create more solutions for patients with cancer. For more information, visit http://www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

SpringWorks Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com